Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI

  • End date
    Aug 1, 2027
  • participants needed
  • sponsor
    Radboud University
Updated on 24 January 2021
coronary artery disease
angina pectoris
acute renal failure
aortic valve stenosis
transcatheter aortic valve implantation
symptomatic aortic stenosis
cardiac mri


Rationale: Transcatheter aortic valve implantation (TAVI) has become the standard therapy for elderly patients with high surgical risks. Paravalvular leakage after TAVI is relatively common and there is conflicting evidence regarding the clinical impact of mild paravalvular leakage in self-expanding devices. Prospective data for self-expanding devices are required to compare the extent of paravalvular leakage as a result of device design. Grading paravalvular leakage after TAVI is difficult. Echocardiography and angiography systematically underestimate paravalvular leakage (PVL) as compared to cardiac MRI. Hemodynamic measurements are used to aid decision making directly after TAVI implantation. Prospective data comparing hemodynamic measurements with cardiac MRI are needed to design an optimal strategy to grade paravalvular leakage peri-operatively in order to optimize TAVI outcomes.

Objective: To assess procedural hemodynamic measurements in patients with paravalvular regurgitation quantified by means of cardiac MRI (CMR) and to analyse its association with impaired clinical outcome during 5-year follow-up.

Study design: This is a prospective, single center clinical trial. Patients will receive a TAVI. After implantation different hemodynamic indices of paravalvular leakage will be assessed. At 1 month a cardiac MRI will be performed to quantify the amount of paravalvular leakage. Standardized clinical follow-up will take place at discharge, 30 days, 3 months and yearly up to 5 years.

Study population: Approximately 80 patients with severe symptomatic aortic valve stenosis with an indication for TAVI will be included.

Intervention: Patients will undergo cardiac MRI on top of standard clinical care within 30 days after TAVI.

Main study parameters/endpoints: The primary endpoint is defined as paravalvular leakage regurgitation fraction as measured by cardiac MRI. The secondary endpoint will comprise a composite of device success, early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)(1) and will comprise death, vascular complications, stroke/ Transient Ischemic Attack (TIA), life threatening bleeding requiring transfusion, and acute kidney injury requiring dialysis.


  1. INTRODUCTION AND RATIONALE Transcatheter aortic valve implantation (TAVI) has become the standard of care in elderly patients with severe symptomatic aortic valve stenosis and increased surgical risks due to advanced age and multiple comorbidity(2-4). However, in contrast to surgical aortic valve replacement (SAVR), paravalvular leakage after TAVI is fairly common. More than moderate paravalvular leakage is associated with intermediate and long-term morbidity and mortality(5).

Since the introduction of TAVI, implantation- and device technology have improved significantly. Nevertheless, mild paravalvular leakage remains a common finding after implantation of new generation devices. Conflicting evidence exists regarding the impact of mild versus none to trivial paravalvular leakage on mortality and morbidity. Several factors might be of influence on these conflicting results. Patients with left ventricular hypertrophy and no previous aortic regurgitation might experience rapidly rising end-diastolic pressures resulting in heart failure even at small regurgitant volumes as seen with mild paravalvular leakage (6-9). Moreover, paravalvular leakage might have greater impact on survival in patients with impaired left ventricular function as compared to patients with preserved left ventricular ejection fraction(10).

Furthermore, studies have used different definitions of paravalvular leakage, assessed paravalvular leakage at different time intervals and used different prostheses. Since paravalvular leakage might decrease over time in self- expandable TAVI devices, this potentially influenced outcomes(11). The widely used VARC-2 criteria for paravalvular leakage grading comprise echocardiographic measurements only(1). Especially quantitative assessment of paravalvular leakage in the intermediate strata (mild-moderate) using echocardiography (TTE) remains difficult. TAVI under conscious sedation or local anesthesia more or less preclude the use of peri-operative trans esophageal echocardiography (TEE). TTE analysis and grading of paravalvular leakage is limited by patient factors such as pulmonary disease, patient habitus and prior cardio-thoracic surgery. Moreover, TTE has been shown to underestimate paravalvular leakage as compared to cardiac MRI(12-14). However,the presence of clinical relevant paravalvular leakage necessitates post-dilatation; therefore grading of paravalvular leakage preferably should be done intra-operatively.

Hemodynamic parameters have been shown to be of great value in grading paravalvular leakage post implantation(15-18). These objective parameters are easily obtained during TAVI and have been shown to have prognostic relevance. All of these parameters are a function of left ventricular end-diastolic pressure (LVEDP). For instance, diastolic delta (DD), defined as the gradient between diastolic aortic pressure and LVEDP, 18 millimetres of mercury (mmHg) was associated with adverse prognosis(15). Heart rate adjusted diastolic delta (HR-DD) (HR-DD= [DD/heartrate] 80) <25 mmHg/beats per minute (BPM) was associated with mortality at 1 year in a retrospective study(16). Combined with angiography and (transesophageal) echocardiography, it was associated with impaired clinical outcome in balloon-expandable bioprostheses (16, 17). Furthermore, the aortic regurgitation index (ARI), defined as the ratio of the diastolic delta to systolic aortic pressure (Aortic regurgitation index = (DD/Aortic pressure systolic)100) >25 combined with angiographic or echocardiographic assessment of paravalvular leakage had a negative predictive value of 95%-100% for the occurrence of more than mild paravalvular leakage. ARI <25 was associated with 1 year mortality, even after adjustment for paravalvular leakage severity(18-20). However, interpretation of ARI is challenging; bradycardia might lead to an ARI <25 without the presence of relevant paravalvular leakage. Determination of ARI should therefore be performed at a heart rate between 60-80 BPM and preferably over several cycles, especially when measured during atrial fibrillation or extrasystoles.

Both echocardiographic and hemodynamic measures provide an estimation of the amount of paravalvular leak. In contrast to echocardiography, MRI provides accurate quantification of paravalvular leakage volume. In this study the investigators want to assess the contributive value of hemodynamic indices of paravalvular leakage based on paravalvular leakage volume measured by means of cardiac MRI and to assess its association with impaired clinical outcomes during 5 year follow-up.

2. OBJECTIVES 2.1 Primary Objective To assess per-procedural hemodynamic indices of paravalvular leakage and to relate these to paravalvular leakage as quantified by cardiac MRI.

2.2 Secondary Objectives To exploratory assess short- and long-term outcomes in patients with different severity of paravalvular leakage

3. STUDY DESIGN The study is designed as a single center, investigator-initiated, clinical trial.

In case patients want to participate there is no change of standard clinical care. After TAVI, study participants will receive additional cardiac MRI within 1 month. Subsequent 3-month and 1-year out-patient clinical follow-up will be performed. Telephone follow-up will be performed after 2,3,4 and 5 years. The end of the study is defined as the day when the last patient completes her/his last visit planned in the protocol.

4. STUDY POPULATION 4.1 Population (base) Patients with severe symptomatic aortic valve stenosis allocated to TAVI by a dedicated heart team will be screened for potential participation. The definition of severe symptomatic aortic valve stenosis is defined in the inclusion criteria.

Condition Aortic Regurgitation, Aortic Stenosis, VALVULAR HEART DISEASE, Heart Valve Disease, Transcatheter Aortic Valve Implantation, Transcatheter Aortic Valve Replacement, Hemodynamic Monitoring, TAVI, Heart Valve Disease, aortic valve stenosis, aortic valve insufficiency, transcatheter aortic valve implant
Treatment Cardiac MRI
Clinical Study IdentifierNCT04281771
SponsorRadboud University
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Patients must be >18 years old
Written informed consent is obtained from all patients
Severe aortic valve stenosis is defined as: jet velocity greater than 4.0m/s or Doppler Velocity index <0.25 or an initial aortic valve area (AVA) of 1.0cm (indexed EOA06 cm/m) as measured by trans thoracic echocardiography <6months prior to inclusion
Patients have symptomatic aortic stenosis, as demonstrated by New York Heart Association (NYHA) functional class 2 or greater or other symptoms of aortic stenosis (e.g. syncope or angina in the absence of coronary artery disease)
Surgical risk is deemed high or intermediate by Society of Thoracic Surgery (STS) risk score or by documented Heart-team agreement due to frailty or co-morbidities
The aortic annulus diameter as measured by ECG-triggered CT-scanning < 6months prior to inclusion meets the ranges indicated in the instructions for use
The access artery diameters (femoral or subclavian) as measured by CT-scanning < 6 months prior to inclusion meet the ranges indicated in the instruction for use
There are no contra-indications (e.g.: severe claustrophobia, metal implants, severe renal failure) for and patient is willing to undergo cardiac MRI at discharge to 30 days after TAVI

Exclusion Criteria

Patient is unwilling or unable to comply with study-required follow-up evaluations
There is evidence of a myocardial infarction within 30 days to index procedure
The presence of severe mitral regurgitation or stenosis
The presence of pre-existing prosthetic cardiac device, valve or prosthetic ring in any position
Left ventricular ejection fraction (LVEF) less than 30%
Untreated significant coronary artery disease requiring revascularization
Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation suggesting active endocarditis
The patient is hemodynamically unstable, requiring inotropic or vasopressive and / or mechanical support
The presence of pulmonary edema or intra venous diuretics to stabilize heart failure at index procedure
Renal insufficiency, defined as a serum creatinin greater than 250umol/l or end-stage renal disease requiring dialysis
Morbid obesity, defined as a BMI 40
A life expectancy of less than one year
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note